Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENAZA-5S: Venetoclax + 5-Day Azacitidine in Treatment-Naïve AML
NCT05833438Phase 2Active, not recruiting
- Sponsor
- Leipzig University
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine in acute myeloid leukemia (AML), sponsored by Leipzig University. Started May 2023; status: active, not recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05833438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833438.